<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Mirabelli M</submitter><funding>Governo Italiano Ministero dell&amp;apos;Istruzione dell&amp;apos;Universita e della Ricerca</funding><funding>Ministero della Salute</funding><funding>Ministero dell’Istruzione, dell’Università e della Ricerca</funding><funding>University College London</funding><pagination>105700</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12019291</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>115</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Growing evidence links tau-related neurodegeneration with insulin resistance and type 2 diabetes (T2D), though the underlying mechanisms remain unclear. Our previous research identified HMGA1 as crucial for insulin receptor (INSR) expression, with defects in the HMGA1 gene associated with insulin resistance and T2D. Here, we explore HMGA1 deficiency as a potential contributor to tauopathies, such as Alzheimer's disease (AD), and its connection to insulin resistance.&lt;h4>Methods&lt;/h4>Immunoblot analyses, protein-DNA interaction studies, ChIP-qPCR, and reporter gene assays were conducted in human and mouse neuronal cell models. Tau immunohistochemistry, behavioural studies, and brain glucose metabolism were analysed in Hmga1-knockout mice. Additionally, a case-control study </pubmed_abstract><journal>EBioMedicine</journal><pubmed_title>HMGA1 deficiency: a pathogenic link between tau pathology and insulin resistance.</pubmed_title><pmcid>PMC12019291</pmcid><funding_grant_id>202279JKW5</funding_grant_id><funding_grant_id>WFR PNRR-MCNT2-2023-12377884</funding_grant_id><funding_grant_id>MUR-PRIN 2022</funding_grant_id><pubmed_authors>Di Vito A</pubmed_authors><pubmed_authors>Greco A</pubmed_authors><pubmed_authors>Fedele M</pubmed_authors><pubmed_authors>Chiefari E</pubmed_authors><pubmed_authors>Brunetti FS</pubmed_authors><pubmed_authors>Nicoletti F</pubmed_authors><pubmed_authors>Pierantoni GM</pubmed_authors><pubmed_authors>Arcidiacono B</pubmed_authors><pubmed_authors>Huin V</pubmed_authors><pubmed_authors>Pascarella A</pubmed_authors><pubmed_authors>Aguglia U</pubmed_authors><pubmed_authors>Salatino A</pubmed_authors><pubmed_authors>Credendino SC</pubmed_authors><pubmed_authors>Mirabelli M</pubmed_authors><pubmed_authors>Morelli M</pubmed_authors><pubmed_authors>Foti DP</pubmed_authors><pubmed_authors>Brunetti A</pubmed_authors></additional><is_claimable>false</is_claimable><name>HMGA1 deficiency: a pathogenic link between tau pathology and insulin resistance.</name><description>&lt;h4>Background&lt;/h4>Growing evidence links tau-related neurodegeneration with insulin resistance and type 2 diabetes (T2D), though the underlying mechanisms remain unclear. Our previous research identified HMGA1 as crucial for insulin receptor (INSR) expression, with defects in the HMGA1 gene associated with insulin resistance and T2D. Here, we explore HMGA1 deficiency as a potential contributor to tauopathies, such as Alzheimer's disease (AD), and its connection to insulin resistance.&lt;h4>Methods&lt;/h4>Immunoblot analyses, protein-DNA interaction studies, ChIP-qPCR, and reporter gene assays were conducted in human and mouse neuronal cell models. Tau immunohistochemistry, behavioural studies, and brain glucose metabolism were analysed in Hmga1-knockout mice. Additionally, a case-control study </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 May</publication><modification>2026-07-15T08:52:30.633Z</modification><creation>2025-07-12T03:04:03.155Z</creation></dates><accession>S-EPMC12019291</accession><cross_references><pubmed>40233659</pubmed><doi>10.1016/j.ebiom.2025.105700</doi></cross_references></HashMap>